People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Technology, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| T2 Biosystems, Inc. | — | Other Technology | Series D+ | $477.6M | $1.3B | 2010 |
| Taris Biomedical Inc | — | Biotechnology | Series B | $36.9M | $535.8M | 2009 |
| SpringLeaf Therapeutics, Inc. | — | Pharmaceuticals | Series B | $34.1M | $647.7M | 2011 |
| GelMEDIX, Inc. | — | Biotechnology | Series A | $9.9M | $1.6M | 2020 |
Michael Cima at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Cima on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Greeley | 3 | 15 |
| Robert Langer | 2 | 36 |
| Kevin Bitterman | 1 | 15 |
| Brian Gallagher | 1 | 11 |
| Alan Crane | 1 | 9 |
| Jeffrey McCarthy | 1 | 7 |
| Robert Crane | 1 | 7 |
| Harry Wilcox | 1 | 6 |
| John McDonough | 1 | 5 |
| Adrian M. Jones | 1 | 5 |
| Kurt Graves | 1 | 5 |
| Diane Marcou | 1 | 5 |
| Christine Bunt | 1 | 4 |
| Cary Pfeffer | 1 | 4 |
| Dennis Ausiello | 1 | 4 |
| Jeffrey Behrens | 1 | 3 |
| Reza Dana | 1 | 3 |
| Purnanand Sarma | 1 | 3 |
| Ed Kania | 1 | 3 |
| PARINAZ MOTAMEDY | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.